Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Opportunities and Challenges in Pharmacovigilance After COVID-19: Signal Detection at Scale

Opportunities and Challenges in Pharmacovigilance After COVID-19: Signal Detection at Scale

Mass vaccination campaigns generated pharmacovigilance data at a volume and speed that the system had not previously handled. This volume represented both the largest opportunity for pharmacovigilance in a generation and its most substantial signal-to-noise problem.

Pubrica AcademyWritten by a pharmacovigilance reviewer Reviewed bya regulatory-writing reviewer Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources2 peer-reviewed

The COVID-19 pandemic, and the mass vaccination campaigns that followed, tested pharmacovigilance systems built around the ICH E2E planning framework at a scale and speed that those systems had not previously encountered, creating both new surveillance capacity and new interpretive challenges in distinguishing genuine signals from the background noise of a much larger reporting volume.

Learning objectives

  • Why mass vaccination campaigns created a pharmacovigilance volume and speed challenge.
  • What distinguishes a background rate coincidence from a genuine safety signal at this scale.
  • How international pharmacovigilance coordination, such as through the Uppsala Monitoring Centre, expanded during this period.
  • Why accelerated approval timelines changed what the pre-approval safety specification could and could not establish.

Common misconceptions

  • “Every adverse event reported after a COVID-19 vaccination was evidence of a vaccine-caused reaction.” At the population scale of a mass vaccination campaign, large numbers of health events will occur coincidentally in the days after vaccination owing to background rates in the population; for this reason, structured causality and disproportionality assessment, rather than raw report counts, is needed to distinguish signal from noise.
  • “Pharmacovigilance for COVID-19 vaccines worked the same way as for a routinely approved medicine.” The reporting volume and accelerated approval timelines of this period meant that safety specifications at authorisation carried more acknowledged uncertainty than usual, which is why enhanced and active surveillance methods, rather than routine passive reporting alone, were emphasised for these products.

Challenges of reporting volume and speed

Mass vaccination campaigns delivering hundreds of millions of doses within a compressed timeframe produced spontaneous adverse event reporting volumes far exceeding those that pharmacovigilance systems, built around the ICH E2E pharmacovigilance planning framework discussed in the article on post-marketing surveillance, had previously processed for a single product. This volume represented an opportunity, since it provided a much larger dataset for detecting rare signals than a typical post-approval period would generate, and a challenge, since the same volume entailed considerably more background noise to be examined before a true signal could be isolated.

Distinguishing coincidental background-rate events from genuine safety signals

At population scale, a large number of health events, including serious events such as cardiac events or strokes, will occur within days of vaccination because the vaccinated population is large and those events have a baseline background rate unrelated to the vaccine. Distinguishing a coincidental background-rate event from a genuine vaccine-attributable signal requires comparison of observed event rates with expected background rates in a comparable unvaccinated population, which is a more demanding analytic task than counting reports, and one that pharmacovigilance systems had to scale up to meet during this period.

Expansion of international pharmacovigilance coordination

The World Health Organization’s Uppsala Monitoring Centre, which coordinates international pharmacovigilance data collection and signal detection, expanded its role during this period to support global monitoring of COVID-19 vaccine safety data across the international reporting network of the WHO, consistent with its stated mission of supporting the safer use of medicines and vaccines globally. This expanded coordination role illustrates one of the lasting opportunities of this period: a stronger international infrastructure for pooling and analysing safety data at a scale that individual national systems could not achieve alone.

Key points

Key points

Mass COVID-19 vaccination campaigns pushed pharmacovigilance systems to a reporting volume and speed they had not previously faced, which created both an opportunity for detecting rare signals at unprecedented scale and a harder challenge of separating genuine signals from background-rate coincidences -- met partly through expanded international coordination through bodies such as the WHO's Uppsala Monitoring Centre.

Practical application

Practical application

  1. Observed event rates should be compared with expected background rates. Before a cluster of reported events is treated as a signal, the observed rate should be compared with the expected background rate in a comparable unvaccinated population of the same size and demographic profile.
  2. Signal-detection capacity should be scaled to reporting volume. Where reporting volume increases sharply, analytic capacity for disproportionality and signal-detection analysis should be scaled accordingly, rather than reliance being placed on manual review processes designed for routine volumes.
  3. International pharmacovigilance coordination should be used where available. Pooled, internationally coordinated safety data (such as those available through the World Health Organization’s Uppsala Monitoring Centre network) should be used where a national dataset alone lacks the scale to detect a rare signal reliably.

Frequently asked questions

Not on its own; the number must be compared with the expected background rate of those events, given the size and demographic profile of the vaccinated population, before any safety conclusion is drawn.

No. It is a WHO collaborating centre that supports international pharmacovigilance data collection and signal detection, working alongside, rather than in place of, national regulatory authorities.

Accelerated approval meant a smaller pre-approval safety database at the time of authorisation, which is specifically why enhanced and active post-approval surveillance was emphasised to compensate, rather than monitoring being reduced overall.

References

  1. International Council for Harmonisation. ICH Harmonised Guideline E2E: Pharmacovigilance Planning. read 10 October 2026. View ICH E2E guideline (PDF)
  2. Uppsala Monitoring Centre. Our vision and mission. read 10 October 2026. View Uppsala Monitoring Centre

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Opportunities and Challenges in Pharmacovigilance After COVID-19: Signal Detection at Scale. Pubrica. https://pubrica.com/academy/concepts-definitions/opportunities-and-challenges-faced-by-pharmacovigilance-after-covid-19/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Mass-campaign signal assessment stub

For use when assessing a potential safety signal from a large-scale vaccination or treatment campaign.

Reported event: ____
Observed rate in exposed population: ____
Expected background rate in comparable unvaccinated population: ____
Observed vs. expected comparison: ____
International pharmacovigilance data consulted (Y/N, source): ____
Signal status: coincidental / warrants further investigation / confirmed

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s pharmacovigilance team develops background-rate comparison analyses and signal-detection documentation at the scale required by mass-campaign reporting volumes, and liaises with international pharmacovigilance data sources where a national dataset alone is insufficient.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Background-rate analysis of safety signals from large-scale vaccination or treatment campaigns

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.